Metformin therapy in the management of polycystic ovary syndrome: endocrine ,metabolic and reproductive effects

References

• Dunaif A, Givens JR., Haseltine FP, et al. The Polycystic Ovary Syndrome. Cambridge, MA: Blackwell Scientific Publications, 1992
   Google Scholar
• Poretsky L. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr Rev 1991;12:3–13
   PubMed Web of Science ®Google Scholar
• Franks S, Gharani N, Waterworth D, et al. The genetic basis of polycystic ovary syndrome. Hum Reprod 1997;12.2641–8
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Wang P, Fontaine R, et al. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 1999;48: 511–19
   PubMed Web of Science ®Google Scholar
• Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J 1986;293:355–9
   Google Scholar
• Clayton RN, Ogden V, Hodgkinson J, et al. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? Clin Endocrinol (Oxj) 1992;37:127–34
   PubMed Web of Science ®Google Scholar
• Koivunen R, Laatikainen T, Tomas C, et al. The prevalence of polycystic ovaries in healthy women. Acta Obstet Gynecol Scand 1999;78:137–41
   PubMed Web of Science ®Google Scholar
• Franks S. Polycystic ovary syndrome. N EnglJ Med 1995;333:853–61
   PubMed Web of Science ®Google Scholar
• Nestler JE, Strauss JF. Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocrinol Metab Clin North Am 1991;20:807–23
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Drug treatment of non-insulin dependent diabetes mellitus in the 1990s. Achieve-ments and future developments. Drugs 1997;54: 355–68
   Google Scholar
• Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic uses in non-insulin-dependent diabetes mellitus. Drugs 1995;49:721–49
   Google Scholar
• Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:550–4
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Turner RC. Metformin drug therapy. N Engl J Med 1996;334:574–9
   PubMed Web of Science ®Google Scholar
• Huckabee WE. Lactic acidosis. Am J Cardiol 1963; 12:663–6
   PubMed Web of Science ®Google Scholar
• Heaney D, Majid A, Junor B. Bicarbonate haemodialysis as a treatment of metformin over-dose. Nephrol Dial Transplant 1997;12:1046–7
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17a activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335:617–23
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800
   PubMed Web of Science ®Google Scholar
• Morales AJ, Laughlin GA, Butzow T, et al. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996;81:2854–64
   PubMed Web of Science ®Google Scholar
• Bringer J, Lefebvre P, Boulet F, et al. Body compo-sition and regional fat distribution in polycystic ovarian syndrome. Relationship to hormonal and metabolic profiles. Ann NY Acad Sci 1993;687: 115–23
   PubMed Web of Science ®Google Scholar
• Holte J. Disturbances in insulin secretion and sensi-tivity in women with the polycystic ovary syn-drome. Baillière's Clin Endocrinol Metab 1996;10: 221–47
   PubMed Web of Science ®Google Scholar
• Barbieri RL, Makris A, Randall RW, et al. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyp er-androgenism. J Clin Endocrinol Metab 1956;62: 904–10
   Google Scholar
• Moghetti P, Castello R, Negri C, et al. Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyp erandro genic women: apparent relative impair-ment of 17,20-lyase activity. J Clin Endocrinol Metab 1996;81:881–6
   PubMed Web of Science ®Google Scholar
• Unluhizarci K, Kelestimur F, Bayram F, et al. The effects of metformin on insulin resistance and ovar-ian s teroido genesis in women with polycystic ovary syndrome. Clin Endocrinol (Oxj) 1999;51:231–6
   PubMed Web of Science ®Google Scholar
• Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139–46
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Kouli C, Tsianateli T, et al. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. EurJEndocrinol1998;138:269–74
   Google Scholar
• Kolodziejczyk B, Duleba AJ, Spaczynski RZ, et al. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000;73:1149–54
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541–9
   PubMed Web of Science ®Google Scholar
• Morin-Papunen LC, Vauhkonen I, Koivunen RM, et al. Endocrine and metabolic effects of metformin versus ethinyl estradiol—cyproterone acetate in obese women with polycystic ovary syn-drome: a randomized study. J Clin Endocrinol Metab 2000;85:3161–8
   Google Scholar
• Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hyp o caloric diet on body composition, fat distribu-tion, and androgen and insulin levels in abdomi-nally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85: 2767–74
   PubMed Web of Science ®Google Scholar
• De Leo V, la Marca A, Orvieto R, et al. Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein Tin polycystic ovary syn-drome. J Clin Endocrinol Metab 2000;85:1598–600
   PubMed Web of Science ®Google Scholar
• Bergh C, Carlsson B, Olsson JH, et al. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril 1993;59:323–31
   PubMed Web of Science ®Google Scholar
• Suikkari AM, Koivisto VA, Rutanen EM, et al. Insulin regulates the serum levels oflow molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 1988;66:266–72
   PubMed Web of Science ®Google Scholar
• Gilling-Smith C, Story H, Rogers V, et al. Evi-dence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxj) 1997;47:93–9
   Google Scholar
• Carmina E, Koyama T, Chang L, et al. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in poly-cystic ovary syndrome? Am J Obstet Gynecol 1992; 167:1807–12
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995;16:322–53
   Google Scholar
• Zhang LH, Rodriguez H, Ohno S, et al. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Nat/ Acad Sci USA 1995;92:10619–23
   PubMed Web of Science ®Google Scholar
• la Marca A, Egbe TO, Morgante G, et al. Met-formin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Hum Reprod 2000;15:21–3
   PubMed Web of Science ®Google Scholar
• Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647–54
   PubMed Web of Science ®Google Scholar
• Crave JC, Fimbel S, Lejeune H, et al. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995;80:2057–62
   PubMed Web of Science ®Google Scholar
• Vandermolen DT, Ratts VS, Evans WS, et al. Metformin increases the ovulatory rate and preg-nancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001;75: 310–15
   PubMed Web of Science ®Google Scholar
• Horton R, Pasupuletti V, Antonipillai I. Androgen induction of steroid 5 alpha-reductase may be mediated via insulin-like growth factor-I. Endo-crinology 1993;133: 447–51
   Google Scholar
• Homburg R, Pariente C, Lunenfeld B, et al. The role of insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) in the patho-genesis of polycystic ovary syndrome. Hum Reprod 1992;7:1379–83
   PubMed Web of Science ®Google Scholar
• Conn JJ, Jacobs HS. Managing hirsutism in gynae-cological practice. Br J Obstet Gynaecol 1998;105: 687–96
   PubMedGoogle Scholar
• Pasquali R, Casimirri F, Venturoli S, et al. Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabo-lism 1994;43:706–13
   PubMed Web of Science ®Google Scholar
• Jakubowicz DJ, Nestler JE. 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and with-out polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab 1997;82:556–60
   PubMed Web of Science ®Google Scholar
• Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxj) 1992;36:105–11
   PubMed Web of Science ®Google Scholar
• Acbay 0, Gundogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 1996;65:946–9
   Google Scholar
• Kowalska I, Kinalski M, Straczkowski M, et al. Insulin, leptin, IGF-I and insulin-dependent pro-tein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. Eur J Endocrinol 2001;144:509–15
   PubMed Web of Science ®Google Scholar
• Morin-Papunen LC, Koivunen RM, Tomas C, et al. Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2566–8
   Google Scholar
• Olson BR, Scott DC, Wetsel WC, et al. Effects of insulin-like growth factors I and II and insulin on the immortalized hypothalamic GTI-7 cell line. Neuroendocrinology 1995;62:155–65
   PubMed Web of Science ®Google Scholar
• Franks S, Mason H, Willis D. Follicular dynamics in the polycystic ovary syndrome. Mol Cell Endo-crinol 2000;163:49–52
   PubMed Web of Science ®Google Scholar
• Murakawa H, Hasegawa I, Kurabayashi T, et al. Polycystic ovary syndrome. Insulin resistance and ovulatory responses to domiphene citrate. J Reprod Med 1999;44:23–7
   Google Scholar
• Velazquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997;90:392–5
   Google Scholar
• Morin-Papunen LC, Koivunen RM, Ruokonen A, et al. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998;69:691–6
   Google Scholar
• Nestler JE, Jakubowicz DJ, Evans WS, et al. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syn-drome. N Engl J Med 1998;338:1876–80
   PubMed Web of Science ®Google Scholar
• De Leo V, la Marca A, Ditto A, et al. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999;72:282–5
   PubMed Web of Science ®Google Scholar
• Pirwany IR, Yates RW, Cameron IT, et al. Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea. Hum Reprod 1999;14:2963–8
   PubMed Web of Science ®Google Scholar
• Clifford K, Rai R, Watson H, et al. An informative protocol for the investigation of recurrent mis-carriage: preliminary experience of 500 consecu-tive cases. Hum Reprod 1994;9:1328–32
   PubMed Web of Science ®Google Scholar
• Rai R, Backos M, Rushworth F, et al. Polycystic ovaries and recurrent miscarriage — a reappraisal. Hum Reprod 2000;15:612–15
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Wang P, Fontaine RN, et al. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999;48:1589–95
   PubMed Web of Science ®Google Scholar
• Clifford K, Rai R, Watson H, et al. Does suppress-ing luteinising hormone secretion reduce the mis-carriage rate? Results of a randomised controlled trial. Br Med J 1996;312:1508–11
   PubMed Web of Science ®Google Scholar
• Lobo RA, Carmina E. The importance of diagnos-ing the polycystic ovary syndrome. Ann Intern Med 2000;132:989–93
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Awadalla SG, Phillips H, et al. Poly-cystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage. Fertil Steril 2000;74:394–7
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Phillips H, Cameron D, et al. Con-tinuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001;75:46–52
   PubMed Web of Science ®Google Scholar
• Jakubowicz DJ, Seppala M, Jakubowicz S, et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:126–33
   Web of Science ®Google Scholar
• Stadtmauer LA, Toma SK, Riehl RM, et al. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modula-tion of the insulin-like growth factors. Fertil Steril 2001;75:505–9
   PubMed Web of Science ®Google Scholar